Key Indicators: Cencora's Financial Health Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong ...

Cencora is updating its outlook for fiscal year 2025. The Company does not provide forward-looking guidance on a GAAP basis as discussed below in Fiscal Year 2025 Expectations. Adjusted diluted ...

For the next fiscal year, the company is expected to earn $16.52 per share on $339.6 billion in revenues. This represents a year-over-year change of 9.52% and 6.76%, respectively. Cencora may be ...

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, a global healthcare company, has significantly expanded the number and type of medications available in its sure supply program, a drug shortage ...

The latest sale netted about $300 million for Walgreens, and shrinks the company’s stake in Cencora to approximately 6%, down from 10%, according to a press release on Thursday. Walgreens said ...

Walgreens Boots Alliance has sold more shares of drug distributor Cencora for proceeds of about $300 million, “primarily for debt paydown and general corporate purposes,” the company said ...

We believe Cencora is well positioned to enjoy these dynamics and expect it to maintain a leading position over our forecast period. The company has partnerships with some of the biggest customers ...

CONSHOHOCKEN, Pa., February 05, 2025--Cencora, Inc. (NYSE: COR) reported that in its fiscal year 2025 first quarter ended December 31, 2024, revenue increased 12.8 percent year-over-year to $81.5 ...

Cencora is updating its outlook for fiscal year 2025. The Company does not provide forward-looking guidance on a GAAP basis as discussed below in Fiscal Year 2025 Expectations. Adjusted diluted EPS ...